A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

Inclusion Criteria:

• Age ≥ 12 to < 18 years at Day 1.

• Diagnosis of AD (according to American Academy of Dermatology Consensus Criteria [Eichenfield et al, 2014]) that has been present for at least 12 months beforesigning of informed consent.

• Body weight ≥ 40 kg at screening.

• History of inadequate response to TCS of medium to higher potency (with or withoutTCI).

• EASI score ≥ 12 at initial screening.

• EASI score ≥ 16 at Day 1.

• vIGA-AD score ≥ 3.

• ≥10% body surface area of AD involvement.

• Worst pruritus NRS ≥ 4.

Exclusion Criteria:

• Treatment with a biological product within 12 weeks or 5 half-lives, whichever islonger, prior to Day 1.

• Treatment with any of the following medications or therapies within 4 weeks or 5half-lives, whichever is longer, prior to Day 1:

1. Systemic corticosteroids

2. Non-biologic, non-targeted systemic immunosuppressants

3. Phototherapy

4. Oral or Topical Janus kinase inhibitors

• Treatment with any of the following medications or therapies within 1 week, prior toDay 1:

1. TCS of any potency

2. TCI

3. Topical phosphodiesterase 4 inhibitors

4. Other topical immunosuppressive agents